Despite the fact that today statins are the first line of treatment against hypercholesterolemia (competitive HMG-CoA reductase inhibitors), these drugs are often considered insufficient in preventing cardiovascular diseases (Gilad and Lampl, 1999; Huynh et al., 2002). This evidence concerns the gene HMGCR and familial hypercholesterolemia.